Text Version
RSS Feeds
Newsletter
Home Forum Photos Features Newsletter Archive Employment
About US Help Site Map
SEARCH   About US FAQ Site Map Site News
  SERVICES
  -Text Version
  -RSS Feeds
  -Newsletter
  -News Archive
  -Give us feedback
  -Voices of Readers
  -Online community
  -China Biz info
  What's new
China considers 24-hour deadline for recall of seriously harmful
drugs
+ -
16:56, September 20, 2007

 Related News
 China to tighten control of medical appliances after heart pump allegations
 China's pharmarceutical watchdog vows to tighten approval procedures (2)
 China's pharmarceutical watchdog vows to tighten approval procedures
 Comment  Tell A Friend
 Print Format  Save Article
Pharmaceutical manufacturers would be given a 24-hour deadline to recall problem drugs that could cause serious harm to takers in a draft plan on China's drug safety.

The State Food and Drug Administration (SFDA) published a draft on drug recall on Thursday to solicit public feedback.

It classified the problem drugs that must be recalled into three categories, with the first being potentially fatal and harmful drugs, which must be recalled in 24 hours.

The second category was drugs that may cause temporary health problems and producers had three days to recall these.

The third category was drugs that must be recalled within seven days for other reasons such as improper packaging.

The plan requires manufacturers to promptly analyse information and feedback from hospitals, retailers and users, and to investigate and evaluate potentially unsafe drugs.

If a potential danger is confirmed, the makers must recall the product, inform retailers, users and the public of the possible effects.

The draft allows the government to revoke the manufacturing license if the drugs cause serious harm or the makers fail to recall the drugs or inform the pubic promptly.

If retailers and hospitals find problems, they must immediately stop selling and using the product, inform the makers and providers, and submit a timely report to the quality supervision authorities.

If they fail to do so, they face fines ranging from 1,000 (132 U.S. dollars) to 50,000 yuan or revocation of licenses in serious cases.

On Sept. 16, the Shanghai municipal government ordered Shanghai Hualian Pharmaceutical Co. to recall leukemia drugs methotrexate and cytarabine hydrochloride after they had caused adverse reactions, including difficulty in walking and retention of urine, in some patients.

The government has tried to strengthen supervision of pharmaceutical and biological products this year. In July, the SFDA revoked the production license of Guangdong Baiyi Pharmaceutical Company for making blood products from a donor infected with hepatitis C.

Source: Xinhua



  Your Message:   Most Commented:
Discussion: China dealing with climate change
Chinese president leaves for Australia
Guest Say: The art of recovering real life on the land
China, Japan vow to enhance defense cooperation

|About Peopledaily.com.cn | Advertise on site | Contact us | Site map | Job offer|
Copyright by People's Daily Online, All Rights Reserved

http://english.people.com.cn/90001/90782/6267480.pdf